Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

221.09USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$221.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,847
52-wk High
$226.23
52-wk Low
$115.52

Chart for

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $2,981.39
Shares Outstanding(Mil.): 21.05
Dividend: --
Yield (%): --

Financials

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

10 May 2018

BRIEF-Ligand Reports Q1 Adjusted Earnings Per Share $1.55

* Q1 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

13 Apr 2018

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

30 Mar 2018

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

23 Mar 2018

BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences

* LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​

07 Mar 2018

BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant

* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION

07 Mar 2018

BRIEF-Ligand Pharma Signs License Agreement

* LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972 Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31

* LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

22 Feb 2018

BRIEF-Ferring Says Specific Financial Details Of Transaction With Ligand Pharma Are Not Disclosed​

* FERRING ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH LIGAND

22 Jan 2018

Earnings vs. Estimates